PRODUCTS & SERVICES
Custom Oligonucleotides Services
We would like to announce that our proposal for the SME instrument phase 2 grant passed through the first round of evaluators. MultiplexDX achieved a score of 14,48 out of 15,00 points, the highest score in the history of Slovak companies. Overall, in the first round of evaluation, our company finished 11th out of 2025 projects. A multinational panel of experts from technology, business and finance sectors judged different aspects of the proposals, including the technology, market knowledge, commercialization plan, and the financials; evaluators considered three main criteria: impact, excellence, and implementation. In contrast to other programs, the evaluation of the phase 2 proposal now includes a face-to-face interview. Unfortunately, MultiplexDX as a newcomer did not pass through the interview phase. However, we are thrilled and honored to be selected among so many prestigious, innovative companies and will use this experience to bolster our efforts to achieve success in the next funding round set in October this year. Keep your fingers crossed for us and for all oncological patients in the EU.
CEO of MultiplexDX, Dr. Pavol Cekan, commented:
„On one hand, we are delighted by the success of achieving such a high score in the first round; on the other, we are disappointed that we failed the interview. I hope we will succeed in the next submission of our proposal. For Slovakia, Slovakian SMEs and our startup ecosystem, it would be a huge breakthrough moment.“
The SME Instrument Horizon 2020 supports the most innovative European companies and startups. The EU commission provides companies with opportunities to get funding for their innovative tech projects. If the SME already has a sound business plan with commercial potential and breakthrough innovation, the SME instrument phase 2 funding offers between €0,5 and €2,5 million in grant form. The outcome of a phase 2 project is an innovative product, process or service that is ready to conquer the market.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.